|
Amicus Therapeutics, Inc. (dobra) Avaliação DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Amicus Therapeutics, Inc. (FOLD) Bundle
Seja você um investidor ou analista, esta calculadora DCF (dobra) é o seu recurso preferido para uma avaliação precisa. Pré -carregado com dados reais da Amicus Therapeutics, Inc., você pode ajustar as previsões e observar instantaneamente os efeitos.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 260.9 | 305.5 | 329.2 | 399.4 | 528.3 | 631.9 | 755.9 | 904.1 | 1,081.4 | 1,293.6 |
| Revenue Growth, % | 0 | 17.11 | 7.76 | 21.3 | 32.29 | 19.61 | 19.61 | 19.61 | 19.61 | 19.61 |
| EBITDA | -243.0 | -202.9 | -199.6 | -92.1 | 29.4 | -300.4 | -359.3 | -429.7 | -514.0 | -614.8 |
| EBITDA, % | -93.14 | -66.4 | -60.62 | -23.06 | 5.56 | -47.53 | -47.53 | -47.53 | -47.53 | -47.53 |
| Depreciation | 8.8 | 6.2 | 5.3 | 7.9 | 8.5 | 13.4 | 16.1 | 19.2 | 23.0 | 27.5 |
| Depreciation, % | 3.39 | 2.03 | 1.62 | 1.97 | 1.62 | 2.13 | 2.13 | 2.13 | 2.13 | 2.13 |
| EBIT | -251.8 | -209.1 | -204.9 | -100.0 | 20.8 | -313.8 | -375.3 | -449.0 | -537.0 | -642.4 |
| EBIT, % | -96.53 | -68.44 | -62.24 | -25.03 | 3.95 | -49.66 | -49.66 | -49.66 | -49.66 | -49.66 |
| Total Cash | 483.3 | 482.5 | 293.6 | 286.2 | 249.9 | 515.8 | 617.0 | 738.0 | 882.8 | 1,055.9 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 46.9 | 52.7 | 66.2 | 87.6 | 101.1 | 121.8 | 145.7 | 174.3 | 208.5 | 249.4 |
| Account Receivables, % | 17.99 | 17.24 | 20.11 | 21.94 | 19.14 | 19.28 | 19.28 | 19.28 | 19.28 | 19.28 |
| Inventories | 19.6 | 26.8 | 23.8 | 59.7 | 118.8 | 77.0 | 92.1 | 110.2 | 131.8 | 157.7 |
| Inventories, % | 7.5 | 8.78 | 7.23 | 14.95 | 22.48 | 12.19 | 12.19 | 12.19 | 12.19 | 12.19 |
| Accounts Payable | 17.1 | 21.5 | 15.4 | 15.1 | 12.9 | 31.0 | 37.0 | 44.3 | 53.0 | 63.4 |
| Accounts Payable, % | 6.54 | 7.04 | 4.68 | 3.79 | 2.45 | 4.9 | 4.9 | 4.9 | 4.9 | 4.9 |
| Capital Expenditure | -3.2 | -3.9 | -3.8 | -7.4 | -3.6 | -7.8 | -9.4 | -11.2 | -13.4 | -16.0 |
| Capital Expenditure, % | -1.24 | -1.27 | -1.14 | -1.86 | -0.67254 | -1.24 | -1.24 | -1.24 | -1.24 | -1.24 |
| Tax Rate, % | -95.11 | -95.11 | -95.11 | -95.11 | -95.11 | -95.11 | -95.11 | -95.11 | -95.11 | -95.11 |
| EBITAT | -254.2 | -216.8 | -200.3 | -100.9 | 40.7 | -312.4 | -373.6 | -446.9 | -534.6 | -639.4 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -298.0 | -223.0 | -215.3 | -158.1 | -29.1 | -267.7 | -399.9 | -478.3 | -572.1 | -684.3 |
| WACC, % | 7.47 | 7.47 | 7.43 | 7.47 | 7.47 | 7.46 | 7.46 | 7.46 | 7.46 | 7.46 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1,887.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -698 | |||||||||
| Terminal Value | -12,787 | |||||||||
| Present Terminal Value | -8,924 | |||||||||
| Enterprise Value | -10,811 | |||||||||
| Net Debt | 230 | |||||||||
| Equity Value | -11,041 | |||||||||
| Diluted Shares Outstanding, MM | 304 | |||||||||
| Equity Value Per Share | -36.27 |
What You Will Get
- Real FOLD Financial Data: Pre-filled with Amicus Therapeutics’ historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Amicus Therapeutics’ intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for Amicus Therapeutics, Inc. (FOLD).
- WACC Tool: Pre-configured Weighted Average Cost of Capital sheet with adjustable inputs specific to the biotech sector.
- Customizable Forecast Assumptions: Adjust growth projections, capital expenditures, and discount rates to fit Amicus Therapeutics' strategy.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios relevant to Amicus Therapeutics, Inc. (FOLD).
- Interactive Dashboard and Charts: Visual representations that encapsulate essential valuation metrics for streamlined analysis.
How It Works
- Download the Template: Gain immediate access to the Excel-based FOLD DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other variables.
- Instant Calculations: The model will automatically refresh Amicus Therapeutics’ intrinsic value.
- Test Scenarios: Experiment with various assumptions to assess potential changes in valuation.
- Analyze and Decide: Utilize the outcomes to inform your investment or financial analysis.
Why Choose This Calculator for Amicus Therapeutics, Inc. (FOLD)?
- Accuracy: Utilizes real Amicus Therapeutics financial data for precise calculations.
- Flexibility: Allows users to easily adjust and test various input parameters.
- Time-Saving: Eliminates the need to create a DCF model from the ground up.
- Professional-Grade: Crafted with the expertise and attention to detail expected at the CFO level.
- User-Friendly: Intuitive design makes it accessible for users with varying levels of financial modeling knowledge.
Who Should Use This Product?
- Investors: Accurately assess Amicus Therapeutics’ fair value before making investment choices.
- CFOs: Utilize a professional-grade DCF model for financial analysis and reporting.
- Consultants: Efficiently modify the template for client valuation reports.
- Entrepreneurs: Acquire insights into financial modeling practices of leading biotech firms.
- Educators: Employ it as a teaching resource to illustrate valuation techniques.
What the Template Contains
- Comprehensive DCF Model: Editable template featuring detailed valuation calculations.
- Real-World Data: Amicus Therapeutics, Inc.'s (FOLD) historical and projected financials preloaded for analysis.
- Customizable Parameters: Adjust WACC, growth rates, and tax assumptions to evaluate different scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage metrics.
- Dashboard with Visual Outputs: Charts and tables providing clear, actionable results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.